RTM-1000: A Brain-Penetrant Clinical Candidate cGAS Inhibitor with Cross-Species Activity, Efficacy in Trex1⁻/⁻ Mice, and Potential for CNS Autoimmune Indications (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1239; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "RTM-1000 is a differentiated clinical candidate cGAS inhibitor with cross-species activity and CNS penetrance. By blocking the most upstream node of the cGAS-STING pathway, RTM-1000 suppresses Type I IFN and TBK1/IRF3-driven inflammatory signaling with demonstrated efficacy across both peripheral and CNS compartments, representing a novel therapeutic approach for autoimmune and CNS diseases driven by aberrant cGAS-STING activation. Figure 1."
Preclinical • CNS Disorders • Immunology • Inflammatory Arthritis • Lupus • Renal Disease • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • CGAS • IFNB1 • TREX1
|
|
Yiqian Wang, Pingping Wang, Shanshan He, Yuanqing Li, Fushan Li, Hao Zhang; Wei Long
|